US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aardvark Therapeutics

12.32

-0.0900-0.73%

Post-market: 12.30-0.0165-0.13%17:01 EST

Volume:51.21K

Turnover:623.87K

Market Cap:267.31M

PE:-5.49

High:12.49

Open:12.30

Low:12.00

Close:12.41

52wk High:19.58

52wk Low:4.88

Shares:21.70M

Float Shares:5.89M

Volume Ratio:0.87

T/O Rate:0.87%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2430

EPS(LYR):-0.7400

ROE:-48.06%

ROA:-30.81%

PB:2.18

PE(LYR):-16.65

Loading ...

Overview Company News Filings

BRIEF-Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Aardvark Therapeutics Grants Stock Options to New Employees

BRIEF-Aardvark Therapeutics Announces Establishment Of New U.S. Subsidiary

Aardvark Therapeutics Launches Ardia Subsidiary for Dermatology Pipeline Expansion

Aardvark Therapeutics Appoints Derrick C. Li as Chief Business Officer and Expands Nelson Sun's Role

Bryan Jones Named CEO as Aardvark Therapeutics Launches Ardia Subsidiary

Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer

THOMSON REUTERS

Aardvark Therapeutics Announces Leadership Appointments

Aardvark Therapeutics Price Target Maintained With a $26.00/Share by BTIG

BRIEF-Aardvark Therapeutics Announces FDA Submission And Irb Approval Of Amended Trial Protocol

Aardvark announces FDA submission, IRB approval of amended trial protocol

Aardvark Therapeutics Receives IRB Approval for Expanded Phase 3 HERO Trial Eligibility

Aardvark Therapeutics Announces FDA Submission and Irb Approval of Amended Trial Protocol for Lead Candidate Ard-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

THOMSON REUTERS

Aardvark Therapeutics Inc - Hero Trial Enrollment on Track to Report Data Q3 2026

THOMSON REUTERS

Aardvark Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

B. Riley Initiates Aardvark Therapeutics at Buy With $32 Price Target

MT Newswires Live

Aardvark Therapeutics Inc : B. Riley Initiates Coverage With Buy Rating; Target Price $32

THOMSON REUTERS

Aardvark Therapeutics initiated with a Buy at B. Riley

Ten new option listings and two option delistings on January 22nd

Aardvark Therapeutics: Clinical Momentum and 2026 Catalyst Stack Underpin Buy Rating and $26 Target

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/AARD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":12.32,"timestamp":1771621200000,"preClose":12.41,"halted":0,"volume":51213,"hourTrading":{"tag":"盘后","latestPrice":12.3035,"preClose":12.32,"latestTime":"17:01 EST","volume":1081,"amount":13310.165,"timestamp":1771624878549,"change":-0.0165,"changeRate":-0.001339,"amplitude":0.001339},"delay":0,"changeRate":-0.007252215954875089,"floatShares":5888000,"shares":21696893,"eps":-2.243,"marketStatus":"Market Closed","change":-0.09,"latestTime":"02-20 16:00:00 EST","open":12.3,"high":12.4931,"low":12,"amount":623868.111003,"amplitude":0.039734,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.243,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":12.41,"preHourTrading":{"tag":"盘前","latestPrice":12.3,"preClose":12.41,"latestTime":"09:29 EST","volume":126,"amount":1550.800188,"timestamp":1771597799968,"change":-0.11,"changeRate":-0.008864,"amplitude":0.000806},"postHourTrading":{"tag":"盘后","latestPrice":12.3035,"preClose":12.32,"latestTime":"17:01 EST","volume":1081,"amount":13310.165,"timestamp":1771624878549,"change":-0.0165,"changeRate":-0.001339,"amplitude":0.001339},"volumeRatio":0.865383,"impliedVol":0.8665,"impliedVolPercentile":0.5238},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AARD\",,,,,undefined,":{"symbol":"AARD","floatShares":5888000,"roa":"-30.81%","roe":"-48.06%","lyrEps":-0.74,"volumeRatio":0.865383,"shares":21696893,"dividePrice":0,"high":12.4931,"amplitude":0.039734,"preClose":12.41,"low":12,"week52Low":4.88,"pbRate":"2.18","week52High":19.58,"institutionHeld":0,"latestPrice":12.32,"eps":-2.243,"divideRate":0,"volume":51213,"delay":0,"ttmEps":-2.243,"open":12.3,"prevYearClose":13.125,"prevWeekClose":12.1,"prevMonthClose":12.99,"prevQuarterClose":13.125,"fiveDayClose":12.28,"twentyDayClose":15.08,"sixtyDayClose":9.37},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AARD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"AARD","fiscalQuarterEnding":"2025/09","expectedEps":-0.82,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.75},{"market":"US","date":"2025-08-13","symbol":"AARD","fiscalQuarterEnding":"2025/06","expectedEps":-0.52,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-05-14","symbol":"AARD","fiscalQuarterEnding":"2025/03","expectedEps":-0.7,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2025-03-31","symbol":"AARD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AARD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AARD","date":"2026-02-19","current":-5.439144,"percent":0.861111,"low":-51.17654,"twenty":-10.677242,"median":-7.870291,"eighty":-5.932159,"high":-4.13394,"avg":-10.742115,"sd":8.905395,"marketCap":275431890},"quantilePoints":[{"date":"2025-02-21","current":-51.17654,"twenty":-46.993414,"median":-42.216938,"eighty":-39.920668,"marketCap":368880503},{"date":"2025-02-28","current":-39.75453,"twenty":-42.139802,"median":-40.229211,"eighty":-39.232381,"marketCap":286550651},{"date":"2025-03-07","current":-28.243517,"twenty":-40.603022,"median":-39.176012,"eighty":-36.900511,"marketCap":203579269},{"date":"2025-03-14","current":-31.091602,"twenty":-40.336014,"median":-37.766803,"eighty":-30.723725,"marketCap":224108270},{"date":"2025-03-21","current":-27.23482,"twenty":-39.944402,"median":-34.681377,"eighty":-29.198812,"marketCap":196308580},{"date":"2025-03-28","current":-26.404128,"twenty":-39.576524,"median":-30.913597,"eighty":-27.946841,"marketCap":190320955},{"date":"2025-04-04","current":-9.026143,"twenty":-39.119644,"median":-30.068072,"eighty":-27.341623,"marketCap":185830236},{"date":"2025-04-11","current":-7.397773,"twenty":-38.751766,"median":-29.400552,"eighty":-17.252871,"marketCap":152305358},{"date":"2025-04-17","current":-7.977371,"twenty":-38.300819,"median":-28.45119,"eighty":-8.603741,"marketCap":164238114},{"date":"2025-04-25","current":-8.66235,"twenty":-37.766803,"median":-27.946841,"eighty":-8.371497,"marketCap":178340462},{"date":"2025-05-02","current":-11.939711,"twenty":-36.900511,"median":-27.412825,"eighty":-8.371497,"marketCap":245814773},{"date":"2025-05-09","current":-11.307423,"twenty":-34.865316,"median":-26.68597,"eighty":-8.46634,"marketCap":232797221},{"date":"2025-05-16","current":-7.114571,"twenty":-32.693651,"median":-13.552046,"eighty":-8.46634,"marketCap":197215912},{"date":"2025-05-23","current":-7.834638,"twenty":-31.0204,"median":-11.823792,"eighty":-8.360959,"marketCap":217176159},{"date":"2025-05-30","current":-8.061615,"twenty":-30.818661,"median":-11.433881,"eighty":-8.172533,"marketCap":223467976},{"date":"2025-06-06","current":-9.353039,"twenty":-30.367714,"median":-11.107198,"eighty":-8.178795,"marketCap":259266244},{"date":"2025-06-13","current":-8.656453,"twenty":-30.076972,"median":-10.833207,"eighty":-8.210998,"marketCap":239956875},{"date":"2025-06-20","current":-9.454788,"twenty":-30.053238,"median":-10.188135,"eighty":-8.218152,"marketCap":262086713},{"date":"2025-06-27","current":-10.84796,"twenty":-29.697227,"median":-10.664596,"eighty":-8.356744,"marketCap":300705451},{"date":"2025-07-03","current":-10.894921,"twenty":-29.459887,"median":-10.613156,"eighty":-8.365174,"marketCap":302007206},{"date":"2025-07-11","current":-9.861782,"twenty":-29.308323,"median":-10.597502,"eighty":-8.375712,"marketCap":273368592},{"date":"2025-07-18","current":-9.360866,"twenty":-28.618005,"median":-10.433139,"eighty":-8.40036,"marketCap":259483203},{"date":"2025-07-25","current":-10.542714,"twenty":-28.285052,"median":-10.45662,"eighty":-8.474871,"marketCap":292244042},{"date":"2025-08-01","current":-9.4,"twenty":-28.006176,"median":-10.433139,"eighty":-8.577715,"marketCap":260567999},{"date":"2025-08-08","current":-9.368693,"twenty":-27.946841,"median":-10.061366,"eighty":-8.607418,"marketCap":259700162},{"date":"2025-08-15","current":-6.668132,"twenty":-27.567096,"median":-9.861782,"eighty":-8.474871,"marketCap":244307015},{"date":"2025-08-22","current":-5.762071,"twenty":-27.424692,"median":-9.803081,"eighty":-8.329026,"marketCap":211110768},{"date":"2025-08-29","current":-5.027748,"twenty":-27.270421,"median":-9.525229,"eighty":-8.145134,"marketCap":184206621},{"date":"2025-09-05","current":-5.027748,"twenty":-27.074615,"median":-9.478268,"eighty":-8.014507,"marketCap":184206621},{"date":"2025-09-12","current":-4.61321,"twenty":-26.629602,"median":-9.396086,"eighty":-7.797069,"marketCap":169018796},{"date":"2025-09-19","current":-6.685898,"twenty":-23.929853,"median":-9.368693,"eighty":-7.515801,"marketCap":244957921},{"date":"2025-09-26","current":-7.503129,"twenty":-17.043362,"median":-9.298251,"eighty":-7.308831,"marketCap":274899634},{"date":"2025-10-03","current":-9.102059,"twenty":-12.821851,"median":-9.210333,"eighty":-7.389343,"marketCap":333481245},{"date":"2025-10-10","current":-9.824539,"twenty":-12.161077,"median":-9.298251,"eighty":-7.460987,"marketCap":359951454},{"date":"2025-10-17","current":-7.876213,"twenty":-12.040618,"median":-9.212156,"eighty":-7.503145,"marketCap":288568676},{"date":"2025-10-24","current":-6.425331,"twenty":-11.978881,"median":-9.149542,"eighty":-7.334887,"marketCap":235411289},{"date":"2025-10-31","current":-6.194375,"twenty":-11.800608,"median":-9.102059,"eighty":-7.096882,"marketCap":226949500},{"date":"2025-11-07","current":-5.844979,"twenty":-11.619352,"median":-9.083015,"eighty":-6.739195,"marketCap":214148333},{"date":"2025-11-14","current":-6.453893,"twenty":-11.527382,"median":-8.978494,"eighty":-6.599437,"marketCap":236457733},{"date":"2025-11-21","current":-4.209833,"twenty":-11.386619,"median":-8.807467,"eighty":-6.451943,"marketCap":205321954},{"date":"2025-11-28","current":-4.455369,"twenty":-11.26527,"median":-8.719067,"eighty":-6.366112,"marketCap":217297254},{"date":"2025-12-05","current":-5.535729,"twenty":-11.176245,"median":-8.71121,"eighty":-6.20385,"marketCap":269988572},{"date":"2025-12-12","current":-6.968768,"twenty":-11.12541,"median":-8.663092,"eighty":-6.182531,"marketCap":339880775},{"date":"2025-12-19","current":-6.111623,"twenty":-11.06083,"median":-8.610671,"eighty":-6.174808,"marketCap":298076093},{"date":"2025-12-26","current":-6.366088,"twenty":-10.989171,"median":-8.599121,"eighty":-6.172233,"marketCap":310486858},{"date":"2026-01-02","current":-5.859391,"twenty":-10.980741,"median":-8.405995,"eighty":-6.111623,"marketCap":285774195},{"date":"2026-01-09","current":-6.477696,"twenty":-10.894921,"median":-8.362013,"eighty":-6.093766,"marketCap":315930176},{"date":"2026-01-16","current":-6.852697,"twenty":-10.894921,"median":-8.218152,"eighty":-6.111623,"marketCap":334219725},{"date":"2026-01-23","current":-6.732161,"twenty":-10.894921,"median":-8.171191,"eighty":-6.111623,"marketCap":328340941},{"date":"2026-01-30","current":-5.959837,"twenty":-10.857352,"median":-8.086731,"eighty":-6.108052,"marketCap":290673181},{"date":"2026-02-06","current":-5.040192,"twenty":-10.779084,"median":-8.030062,"eighty":-6.020346,"marketCap":245820240},{"date":"2026-02-13","current":-5.482157,"twenty":-10.700911,"median":-7.926792,"eighty":-5.956266,"marketCap":267375780},{"date":"2026-02-19","current":-5.647336,"twenty":-10.677242,"median":-7.870291,"eighty":-5.932159,"marketCap":275431890}],"updateTime":1771615321174},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AARD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611150917","title":"BRIEF-Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611150917","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611150917?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:46","pubTimestamp":1770990387,"startTime":"0","endTime":"0","summary":"BRIEF-Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Feb 13 (Reuters) - Aardvark Therapeutics Inc AARD.O:AARDVARK THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nTUA2TNZP4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2611521771","title":"Aardvark Therapeutics Grants Stock Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2611521771","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611521771?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:00","pubTimestamp":1770987614,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. has granted inducement stock options to six new employees under its 2025 Inducement Equity Incentive Plan. On February 9, 2026, five employees received options to purchase a total of 147,213 shares at an exercise price of $13.48 per share, and on February 11, 2026, one employee received an option for 5,125 shares at an exercise price of $12.67 per share. Each option vests over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 13, 2026, and is solely","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL3Yy8LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014005.SGD","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","LU2210149790.SGD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","AARD","IE00BKPKM429.USD","BK4585","BK4112"],"gpt_icon":0},{"id":"2610987927","title":"BRIEF-Aardvark Therapeutics Announces Establishment Of New U.S. Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2610987927","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610987927?lang=en_us&edition=fundamental","pubTime":"2026-02-12 22:40","pubTimestamp":1770907208,"startTime":"0","endTime":"0","summary":"BRIEF-Aardvark Therapeutics Announces Establishment Of New U.S. Subsidiary Feb 12 (Reuters) - Aardvark Therapeutics Inc AARD.O:AARDVARK THERAPEUTICS ANNOUNCES ESTABLISHMENT OF NEW U.S. SUBSIDIARY TO S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA4MZRKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2610492992","title":"Aardvark Therapeutics Launches Ardia Subsidiary for Dermatology Pipeline Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2610492992","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610492992?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:06","pubTimestamp":1770901615,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the establishment of Ardia Therapeutics, Inc., a new wholly-owned U.S. subsidiary aimed at supporting the development of its dermatology pipeline. Ardia will focus on advancing DIA-615, a potential topical treatment for inflammatory skin diseases such as psoriasis. Bryan Jones, Ph.D., previously Aardvark's Chief Operating Officer, has been appointed Chief Executive Officer of Ardia to lead this new initiative.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL9jMZ57:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2610092958","title":"Aardvark Therapeutics Appoints Derrick C. Li as Chief Business Officer and Expands Nelson Sun's Role","url":"https://stock-news.laohu8.com/highlight/detail?id=2610092958","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610092958?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:01","pubTimestamp":1770901289,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. has appointed Derrick C. Li as Chief Business Officer and expanded Nelson Sun’s role to include Chief Operating Officer in addition to his current position as Chief Financial Officer. These changes are effective as of February 9, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL92vgJm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","BK4112","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","AARD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014039.USD","BK4585","LU2095319765.USD","SG9999014021.USD","NDAQ"],"gpt_icon":0},{"id":"2610929318","title":"Bryan Jones Named CEO as Aardvark Therapeutics Launches Ardia Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2610929318","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610929318?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901225,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. has established a new U.S. subsidiary, Ardia Therapeutics, Inc., to support its dermatology pipeline. Bryan Jones, Ph.D., formerly Chief Operating Officer of Aardvark, has been appointed Chief Executive Officer of Ardia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDLcf6Yb5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4112","IE00BGHQF748.EUR","NDAQ","BK4585","LU2210150020.SGD","SG9999014005.SGD","BK4588","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","AARD","LU2095319765.USD"],"gpt_icon":0},{"id":"2610929828","title":"Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2610929828","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610929828?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901206,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUA4MZRKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2610992780","title":"Aardvark Therapeutics Announces Leadership Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2610992780","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610992780?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  12, 2026  (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutic","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/12/3237145/0/en/Aardvark-Therapeutics-Announces-Leadership-Appointments.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS","AARD"],"gpt_icon":0},{"id":"2610205746","title":"Aardvark Therapeutics Price Target Maintained With a $26.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2610205746","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610205746?lang=en_us&edition=fundamental","pubTime":"2026-02-11 01:50","pubTimestamp":1770745800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2026 12:50 ET (17:50 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2610211276","title":"BRIEF-Aardvark Therapeutics Announces FDA Submission And Irb Approval Of Amended Trial Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2610211276","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610211276?lang=en_us&edition=fundamental","pubTime":"2026-02-10 23:29","pubTimestamp":1770737342,"startTime":"0","endTime":"0","summary":"BRIEF-Aardvark Therapeutics Announces FDA Submission And Irb Approval Of Amended Trial Protocol Feb 10 (Reuters) - Aardvark Therapeutics Inc AARD.O:AARDVARK THERAPEUTICS ANNOUNCES FDA SUBMISSION AND I","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nTUABV2FTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2610962339","title":"Aardvark announces FDA submission, IRB approval of amended trial protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2610962339","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610962339?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:10","pubTimestamp":1770729013,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (AARD) announced that Institutional Review Board, IRB, approval has been granted in the United States for an amended protocol...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-announces-fda-submission-irb-approval-of-amended-trial-protocol-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-announces-fda-submission-irb-approval-of-amended-trial-protocol-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2610662883","title":"Aardvark Therapeutics Receives IRB Approval for Expanded Phase 3 HERO Trial Eligibility","url":"https://stock-news.laohu8.com/highlight/detail?id=2610662883","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610662883?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:00","pubTimestamp":1770728449,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. announced that its amended protocol for the Phase 3 HERO clinical trial evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome has received Institutional Review Board  approval in the United States. The amended protocol, which was also submitted to the U.S. Food and Drug Administration , expands trial eligibility to include children as young as 7 years old, lowering the previous minimum age limit from 10 years. This change aims to broaden access to the trial for younger patients with Prader-Willi Syndrome.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on Februar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLc9JY6T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU0314104364.USD","SG9999014013.SGD","AARD","BK4588","LU2210149790.SGD"],"gpt_icon":0},{"id":"2610640096","title":"Aardvark Therapeutics Announces FDA Submission and Irb Approval of Amended Trial Protocol for Lead Candidate Ard-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2610640096","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610640096?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:00","pubTimestamp":1770728403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nTUABV2FTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2610640086","title":"Aardvark Therapeutics Inc - Hero Trial Enrollment on Track to Report Data Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2610640086","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610640086?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:00","pubTimestamp":1770728403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nTUABV2FTH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2610658510","title":"Aardvark Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2610658510","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610658510?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:55","pubTimestamp":1770641700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AARD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 09, 2026 07:55 ET (12:55 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"gpt_icon":0},{"id":"2606714847","title":"B. Riley Initiates Aardvark Therapeutics at Buy With $32 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2606714847","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606714847?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:35","pubTimestamp":1769607325,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics (AARD) has an average rating of buy and mean price target of $32.64, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AARD"],"gpt_icon":0},{"id":"2606197897","title":"Aardvark Therapeutics Inc : B. Riley Initiates Coverage With Buy Rating; Target Price $32","url":"https://stock-news.laohu8.com/highlight/detail?id=2606197897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606197897?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:03","pubTimestamp":1769605413,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT0RD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AARD"],"gpt_icon":0},{"id":"2606792298","title":"Aardvark Therapeutics initiated with a Buy at B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2606792298","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606792298?lang=en_us&edition=fundamental","pubTime":"2026-01-28 17:55","pubTimestamp":1769594110,"startTime":"0","endTime":"0","summary":"B. Riley analyst William Wood initiated coverage of Aardvark Therapeutics (AARD) with a Buy rating and $32 price target The company is developing A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-initiated-with-a-buy-at-b-riley-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aardvark-therapeutics-initiated-with-a-buy-at-b-riley-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0},{"id":"2605849457","title":"Ten new option listings and two option delistings on January 22nd","url":"https://stock-news.laohu8.com/highlight/detail?id=2605849457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605849457?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:36","pubTimestamp":1769088965,"startTime":"0","endTime":"0","summary":"New option listings for January 22nd include Aardvark Therapeutics Inc (AARD), Anteris Technologies Global Corp (AVR), Climb Bio Inc (CLYM), REX Dr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ten-new-option-listings-and-two-option-delistings-on-january-22nd-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ten-new-option-listings-and-two-option-delistings-on-january-22nd-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVR","AARD","CLYM","BK4539","BK4082"],"gpt_icon":0},{"id":"2604191017","title":"Aardvark Therapeutics: Clinical Momentum and 2026 Catalyst Stack Underpin Buy Rating and $26 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2604191017","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604191017?lang=en_us&edition=fundamental","pubTime":"2026-01-20 18:39","pubTimestamp":1768905557,"startTime":"0","endTime":"0","summary":"Analyst Jeet Mukherjee of BTIG reiterated a Buy rating on Aardvark Therapeutics, Inc., retaining the price target of $26.00. Jeet Mukherjee has giv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/aardvark-therapeutics-clinical-momentum-and-2026-catalyst-stack-underpin-buy-rating-and-26-target-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/aardvark-therapeutics-clinical-momentum-and-2026-catalyst-stack-underpin-buy-rating-and-26-target-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":68,"code":"91000000","status":"200"}]}}